Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes.
The new analgesic tapentadol was evaluated for induction and inhibition of several cytochrome P450 enzymes in vitro, and protein binding was assessed. It was concluded that no clinically relevant drug-drug interactions are likely to occur through either mechanism.
Grünenthal GmbH 52078 Aachen, Germany. Christa.Kneip@grunenthal.com
Christa
C
Kneip
Rolf
R
Terlinden
Horst
H
Beier
Genfu
G
Chen
D000328:Adult; D000368:Aged; D000700:Analgesics / Q000494:pharmacology*; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects* / Q000378:metabolism; D004347:Drug Interactions; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D022781:Hepatocytes / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology; D008875:Middle Aged; D010636:Phenols / Q000494:pharmacology*; D011485:Protein Binding; D000077432:Tapentadol
D000700:Analgesics; D010636:Phenols; D003577:Cytochrome P-450 Enzyme System; D000077432:Tapentadol